Joel Greenblatt's HALO Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 746,841 shares of Halozyme Therapeutics, Inc. (HALO) worth $48.27 M, representing 0.15% of the portfolio. First purchased in 2015-Q2, this long-term strategic position has been held for 36 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in HALO, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 307,133 shares. Largest reduction occurred in Q3 2018, reducing 62,201 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Halozyme Therapeutics (HALO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Halozyme Therapeutics (HALO) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +307,133 | Add 69.85% | 746,841 | $64.63 |
| Q4 2025 | +186,774 | Add 73.84% | 439,708 | $67.30 |
| Q3 2025 | +184,882 | Add 271.68% | 252,934 | $73.34 |
| Q2 2025 | +35,521 | Add 109.19% | 68,052 | $52.02 |
| Q1 2025 | -14,909 | Reduce 31.43% | 32,531 | $63.81 |
| Q4 2024 | +4,178 | Add 9.66% | 47,440 | $47.81 |
| Q3 2024 | +14,886 | Add 52.46% | 43,262 | $57.24 |
| Q2 2024 | -13,537 | Reduce 32.30% | 28,376 | $52.36 |
| Q1 2024 | -55,975 | Reduce 57.18% | 41,913 | $40.68 |
| Q4 2023 | +55,782 | Add 132.48% | 97,888 | $36.96 |
| Q3 2023 | +6,153 | Add 17.11% | 42,106 | $38.20 |
| Q2 2023 | -7,918 | Reduce 18.05% | 35,953 | $36.07 |
| Q1 2023 | +16,424 | Add 59.84% | 43,871 | $38.19 |
| Q4 2022 | -2,143 | Reduce 7.24% | 27,447 | $56.90 |
| Q3 2022 | -905 | Reduce 2.97% | 29,590 | $39.54 |
| Q2 2022 | -8,407 | Reduce 21.61% | 30,495 | $44.01 |
| Q1 2022 | -6,231 | Reduce 13.81% | 38,902 | $39.87 |
| Q4 2021 | +21,698 | Add 92.59% | 45,133 | $40.21 |
| Q3 2021 | -10,943 | Reduce 31.83% | 23,435 | $40.67 |
| Q2 2021 | -11,946 | Reduce 25.79% | 34,378 | $45.41 |
| Q1 2021 | +25,085 | Add 118.11% | 46,324 | $41.68 |
| Q4 2020 | +349 | Add 1.67% | 21,239 | $42.70 |
| Q3 2020 | +8 | Add 0.04% | 20,890 | $26.28 |
| Q2 2020 | +3,153 | Add 17.78% | 20,882 | $26.82 |
| Q1 2020 | +17,729 | New Buy | 17,729 | $17.99 |
| Q4 2019 | -13,334 | Sold Out | 0 | $0.00 |
| Q3 2019 | +364 | Add 2.81% | 13,334 | $15.52 |
| Q2 2019 | +12,970 | New Buy | 12,970 | $17.19 |
| Q3 2018 | -62,201 | Sold Out | 0 | $0.00 |
| Q2 2018 | -53,741 | Reduce 46.35% | 62,201 | $16.86 |
| Q1 2018 | +115,942 | New Buy | 115,942 | $19.59 |
| Q3 2016 | -34,313 | Sold Out | 0 | $0.00 |
| Q2 2016 | +34,313 | New Buy | 34,313 | $8.63 |
| Q4 2015 | -28,955 | Sold Out | 0 | $0.00 |
| Q3 2015 | -7,746 | Reduce 21.11% | 28,955 | $13.43 |
| Q2 2015 | +36,701 | New Buy | 36,701 | $22.59 |
Joel Greenblatt's Halozyme Therapeutics Investment FAQs
Joel Greenblatt first purchased Halozyme Therapeutics, Inc. (HALO) in Q2 2015, acquiring 36,701 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Halozyme Therapeutics, Inc. (HALO) for 36 quarters since Q2 2015.
Joel Greenblatt's largest addition to Halozyme Therapeutics, Inc. (HALO) was in Q1 2026, adding 746,841 shares worth $48.27 M.
According to the latest 13F filing for Q1 2026, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 746,841 shares of Halozyme Therapeutics, Inc. (HALO), valued at approximately $48.27 M.
As of the Q1 2026 filing, Halozyme Therapeutics, Inc. (HALO) represents approximately 0.15% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Halozyme Therapeutics, Inc. (HALO) was 746,841 shares, as reported at the end of Q1 2026.